MIR492

Summary

MIR492 (microRNA 492, HGNC:32081) is a microRNA gene on chromosome 12q22.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 574449 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32081
Approved symbol	MIR492
Name	microRNA 492
Location	12q22
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-492
Ensembl gene	ENSG00000283998
Ensembl biotype	miRNA
OMIM	614384
Entrez	574449
RNAcentral	URS0000476A52 — miRNA, 116 nt, 3 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000638676

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000638676 — 1 exons

Exon	Start	End
ENSE00003802078	94834398	94834513

Expression profiles

Bgee: expression breadth broad, 46 present calls, max score 75.84.

Top tissues by expression

46 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
esophagogastric junction muscularis propria	UBERON:0035841	75.84	gold quality
heart left ventricle	UBERON:0002084	75.45	gold quality
body of pancreas	UBERON:0001150	73.11	gold quality
islet of Langerhans	UBERON:0000006	72.90	gold quality
gastrocnemius	UBERON:0001388	70.20	gold quality
stomach	UBERON:0000945	69.37	gold quality
body of stomach	UBERON:0001161	69.24	gold quality
blood	UBERON:0000178	69.08	gold quality
subcutaneous adipose tissue	UBERON:0002190	68.97	gold quality
esophagus mucosa	UBERON:0002469	68.78	gold quality
ectocervix	UBERON:0012249	68.59	gold quality
lower esophagus muscularis layer	UBERON:0035833	68.13	gold quality
anterior cingulate cortex	UBERON:0009835	67.82	gold quality
minor salivary gland	UBERON:0001830	66.91	gold quality
right ovary	UBERON:0002118	66.89	gold quality
small intestine Peyer’s patch	UBERON:0003454	66.66	gold quality
transverse colon	UBERON:0001157	66.14	gold quality
intestine	UBERON:0000160	66.05	gold quality
skin of leg	UBERON:0001511	65.83	gold quality
omental fat pad	UBERON:0010414	65.53	gold quality
left uterine tube	UBERON:0001303	65.46	gold quality
colon	UBERON:0001155	65.44	gold quality
endocervix	UBERON:0000458	65.34	gold quality
cerebellar hemisphere	UBERON:0002245	65.33	gold quality
right frontal lobe	UBERON:0002810	64.45	gold quality
myometrium	UBERON:0001296	64.37	gold quality
tibial nerve	UBERON:0001323	64.32	gold quality
right atrium auricular region	UBERON:0006631	64.06	gold quality
urinary bladder	UBERON:0001255	63.55	gold quality
upper lobe of left lung	UBERON:0008952	63.00	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 24)

• miR-492 can originate from the coding sequence of the HB marker gene keratin 19 (KRT19) (PMID:21319197)
• study suggests that miR-492 may physiologically suppress BSG expression and the BSG rs8259 polymorphism is associated with decreased psoriasis susceptibility through affecting miR-492 binding. (PMID:21655935)
• miR-492 exerts a potent anti-angiogenic activity in endothelial cells. (PMID:23802567)
• miR-492 contributes to insulin resistance and endothelial dysfunction induced by high glucose, via directly downregulating resistin expression. (PMID:24526524)
• Data indicate that elevated miR-492 expression in prostate tumors that resulted in diminished myeloid zinc-finger 1 (MZF-1) and ferroportin (FPN). (PMID:25284586)
• Ectopic expression of miR-492 led to downregulation of SOX7 protein. (PMID:25407488)
• the present study provided novel insights into the potential mechanisms involved in Clear cell renal cell carcinoma and it is hypothesized that miR-492 may become a promising therapeutic agent in the treatment of Clear cell renal cell carcinoma (PMID:25815441)
• The miR-492/CD147 axis might play an essential role in the Oxaliplatin resistance of colon cancer cells. (PMID:25862460)
• The potential use of miR-492 rs2289030 as a prognostic marker . (PMID:26753964)
• p21-activated kinase (PAK7) was identified as the putative target of miR492 in osteosarcoma (OS), and we further found a significantly inverse correlation between PAK7 and miR492 in OS specimens. (PMID:28677719)
• Data show that tissue inhibitor of metalloproteinase 2 (TIMP2) is a direct target of miR-492 that modulates cervical cancer cell invasion. (PMID:28802022)
• miR-492 may be involved in the regulation of OK antigen expression on red blood cells with the BSG rs8259 TT genotype. (PMID:28981932)
• miR-492 significantly enhances cell proliferation, anchorage-independent growth, migration and invasion of hepatoblastoma cells. High miR-492 expression correlates with high-risk or aggressive tumours and further bears potential for predicting reduced event-free survival. The study identified miR-492 and its target CD44 as regulators of a number of biological features important for malignancy and metastasis. (PMID:29314711)
• Diabetic Cardiovascular Complications are associated with decreased levels of miR-492 suggesting that MIR-492 may be novel biomarkers. (PMID:29459239)
• In conclusion, miR492 inhibition may impede the malignant behaviour of retinoblastoma (RB) by directly targeting LATS2. Therefore, targeting this miRNA may be an effective therapeutic method for treating patients with RB. (PMID:30592270)
• study demonstrated that miR-492 was over-expressed in Prostate Cancer and exerted tumor-promoting function in PCa cells via repressing SOCS2 expression. (PMID:30779065)
• miR-492 promotes chemoresistance to CDDP and metastasis by targeting inhibiting DNMT3B and induces stemness in gastric cancer. (PMID:32065219)
• The overexpression of LATS2 repressed the growth and invasion of ACHN and 786-O cells. circ_0001368 upregulated the LATS2 expression and suppressed ACHN and 786-O cell growth and invasion by sponging miR-492. (PMID:32428698)
• Effects of miR-492 on migration, invasion, EMT and prognosis in ovarian cancer by targeting SOX7. (PMID:32521870)
• Association between miR-492 rs2289030 G>C and susceptibility to Hirschsprung disease in southern Chinese children. (PMID:33103535)
• Association of miRNA-492 rs2289030 G>C and miRNA-938 rs2505901 T>C Gene Polymorphisms with Biliary Atresia Susceptibility. (PMID:34353423)
• The immunogenic involvement of miRNA-492 in mycoplasma pneumoniae infection in pediatric patients. (PMID:36195304)
• NamiRNA-enhancer network of miR-492 activates the NR2C1-TGF-beta/Smad3 pathway to promote epithelial-mesenchymal transition of pancreatic cancer. (PMID:36591938)
• hsa_circ_0129047 Upregulates LYVE1 to Inhibit Hepatocellular Carcinoma Progression by Sponging miR-492. (PMID:37810197)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.